A Study Of PF-03882845 Absorption In Healthy Volunteers Given Orally As Tablet Versus Suspension Formulations And Effect Of Food On Its Absorption

Model scores of the 29,894 trials active now.

Model score 3% for any early termination, 0% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 6% of the time (816 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2011-02-28. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: pfkidneyprimaryused inchildbearing potential
  Phrases that lowered it: bioavailabilitytablethealthycrossoversingle dose
• Accepts healthy volunteers: Yes (lowers risk) · Who can join
• Design: crossover (lowers risk) · Design
• Sponsor's past termination rate: 15.1% (raises risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 402 (raises risk) · Sponsor's track record
• Phase: 1 (lowers risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Has a data monitoring committee: No (lowers risk) · Design
• Maximum age: 55 (lowers risk) · Who can join
• Sponsor's past trials: 875 (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: no FAERS history (raises risk) · Drug's FDA history
• Primary purpose: basic science (lowers risk) · Design
• Drug's FAERS reports marked serious: no FAERS history (raises risk) · Drug's FDA history
• Disease area, neurology: No (lowers risk) · Disease area
• Disease area, cancer: No (lowers risk) · Disease area
• Responsible party: not given (raises risk) · Design
• Disease area, psychiatry: No (lowers risk) · Disease area
• Blinding: none (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Study To Investigate The Safety, Toleration And Pharmacokinetics Of Single Oral Doses Of PF-03864086 In Healthy Male Subjects NCT00747058 · started 2008 · scored riskier than 7% of active trials completed
• A Comparison Of A Single PF-04634817 Tablet Dose Compared With A Solution In Healthy Volunteers NCT01247883 · started 2010 · scored riskier than 2% of active trials completed
• A Phase 1 Study To Evaluate The Safety And Tolerability Of Different Doses Of PF-03893787 In Healthy Adult Volunteers NCT00992342 · started 2009 · scored riskier than 10% of active trials completed
• AStudy to Evaluate the Bioavailability of PF 04965842 in Healthy Subjects NCT02163161 · started 2014 · scored riskier than 1% of active trials completed
• Multiple Dose Study in Healthy Volunteers to Assess Safety, Pharmacokinetics and Pharmacodynamics of PF 03882845 NCT00856258 · started 2009 · scored riskier than 7% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.